Loading organizations...
Synarc has raised $10.0M across 1 funding round.
Key people at Synarc.
Synarc has raised $10.0M in total across 1 funding round.
Synarc provides specialized scientific services, operating as a Contract Research Organization (CRO) for pharmaceutical and biotechnology companies. It focuses on managing and analyzing quantitative imaging and molecular markers for clinical trials across therapeutic areas. Core capabilities include medical image analysis, patient recruitment, and biochemical marker processing, streamlining research protocols.
Synarc was co-founded in 1998 by Harry K. Genant and Thomas Fuerst. Their founding insight addressed a critical need in clinical research for standardized, high-quality quantitative imaging and biomarker management in large-scale studies. Both founders possessed deep expertise, identifying a market gap for services enhancing drug development reliability and efficiency.
Synarc serves pharmaceutical and biotechnology firms, providing crucial data management and analysis for investigational drug development and regulatory submissions. Its vision centers on advancing medical research through precise, consistent data delivery in complex trial environments. By standardizing imaging and molecular data, Synarc aims to accelerate new therapy development and improve patient outcomes.
Synarc is a San Francisco-based company founded in 1998 that provides specialized scientific services to the pharmaceutical industry, focusing on medical imaging and biomarkers to accelerate clinical trials and drug development.[1][2] It serves pharmaceutical and biotechnology firms in domains like oncology, neurology, cardiology, arthritis, and osteoporosis, offering imaging data acquisition, analysis, and management to assess drug efficacy and safety more accurately.[1][2] At Series D stage with $7.1M raised, Synarc solves key challenges in clinical research by reducing trial time, uncertainty, and costs through advanced imaging techniques critical for personalized medicine and regulatory approvals.[1][2]
(Note: A separate entity, Synarc Systems or SYNARC IT Services, appears in results as an IT infrastructure provider for businesses, but the query aligns with the primary Synarc in clinical trials, not general IT.[3][4])
Synarc was founded in 1998 in San Francisco, California, emerging as a pioneer in clinical trial imaging services during the late 1990s boom in biotech and pharma R&D.[1][2] While specific founders are not detailed in available data, the company quickly established expertise in medical imaging biomarkers for drug development, targeting high-need areas like oncology, neurology, and musculoskeletal diseases.[2] Early traction came from supporting global clinical studies, adapting to technological advances and regulatory shifts, with involvement in high-profile trials that solidified its role in accelerating drug timelines.[2] By its Series D funding (last raised $7.1M over 26 years ago from investors like SV Health Investors), Synarc had filed 11 patents, including recent ones in oncology and immunology granted as late as 2024.[1]
Synarc rides the wave of precision medicine and AI-enhanced imaging in clinical trials, where advanced biomarkers are essential for faster FDA approvals amid rising drug development costs exceeding $2B per asset.[2] Its timing aligns with post-2020 regulatory pushes for real-world evidence and imaging endpoints in oncology/neurology trials, fueled by biotech funding surges and tech integration like AI for image analysis.[1][2] Market forces favoring Synarc include pharma's shift to outsourced services (CRO market >$70B) and demand for imaging in 40%+ of trials, positioning it to influence ecosystem efficiency by enabling quicker, data-rich studies that de-risk investments.[2] As a stable player, it supports broader innovation without the volatility seen in pure tech startups.
Synarc's future hinges on expanding AI-driven imaging analytics and biomarker patents to capitalize on personalized medicine's growth, potentially through partnerships or acquisition by larger CROs like ICON or Parexel. Trends like decentralized trials and multimodal data (imaging + genomics) will shape its path, amplifying influence in a market projected to hit $100B+ by 2030. With no major disruptions and recent patent grants, expect steady evolution from niche provider to integral ecosystem enabler, tying back to its core strength in slashing drug development timelines for pharma innovators.[1][2]
Synarc has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series B in March 2004.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2004 | $10M Series B | — | SV Health Investors | Announced |
Key people at Synarc.
Synarc has raised $10.0M in total across 1 funding round.
Synarc's investors include SV Health Investors.
